Antikörper-Wirkstoff-Konjugate beim metastasierten Mammakarzinom

Molecular factors play a crucial role in the development of targeted therapies for metastatic breast cancer.

This study aimed to explore new specific and targeted therapies for metastatic breast cancer.

The latest findings on treatment of metastatic breast cancer with antibody–drug conjugates (ADC) are presented.

Prolonged progression-free survival, improved overall survival, and a lower side effect profile with ADCs compared to conventional chemotherapy could be shown.

ADCs have the potential to enhance survival of patients with metastatic breast cancer.